¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Prostate Cancer"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
¿µ¹® cervix cancer ÇÑ±Û Àڱøñ¾Ï, ÀڱðæºÎ¾Ï
¼³¸í   
  ÀÚ±ÃÀÇ ¸ñÀº ÀÚ±ÃÀÌ Áú°ú ¿¬°áµÈ ºÎÀ§·Î ÀÚ±ÃÀÇ ÀÔ±¸¿¡ ÇØ´çÇϴ ºÎÀ§ÀÌ´Ù. À̰÷ÀÇ »óÇǼ¼Æ÷¿¡¼­ ¹ß»ýÇϴ ¾ÏÀ» Àڱøñ¾ÏÀ̶ó°í ÇÑ´Ù.
  
  Àڱøñ¾ÏÀÇ ¹ß»ýÀ» »ìÆìº¸¸é ÀڱøñÀÇ »óÇǼ¼Æ÷°¡ ¿©·¯ °¡Áö Àڱؿ¡ ÀÇÇØ¼­ Á¤»ó¼¼Æ÷¿Í Â÷À̳ª´Â ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ »ý±â°Ô µÈ´Ù. ÀÌ ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷´Â Ã³À½¿¡´Â ÀڱøñÀÇ »óÇǼ¼Æ÷ÃþÀÇ ÀϺθ¦ ÀÌ·ç°í ÀÖ°Ô µÈ´Ù. ±×·¯´Ù°¡ Á¡Á¡ ´õ ÁøÇàÀÌ µÇ¸é ¾Ï¼º¼¼Æ÷°¡ Àڱøñ »óÇǼ¼Æ÷ÀÇ ¸ðµç ÃþÀ» ²Ëä¿ì°Ô µÈ´Ù. ±×¸®°í °è¼Ó ÁøÇàÇϸ頻óÇǼ¼Æ÷ÀÇ ¸Ç ¹Ø¿¡ Àִ ¹Ù´Ú¸·À» ¶Õ°í ¹öÆÀÁ¶Á÷À¸·Î Ä§À±ÇØ µé¾î°¡°Ô µÈ´Ù. ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀÇ ÀϺθ¦ Ã¤¿ì´Â °ÍÀ» ÀڱøñÇü¼ºÀÌ»ó(cervical dysplasia)¶ó°í ÇÏ°í ¾Ï¼ºº¯È­¸¦ ÇÑ ¼¼Æ÷°¡ ÀÚ±ÃÀÇ »óÇÇÃþÀ» ¸ðµÎ Ã¤¿ö¹ö·Á Á¤»óÀûÀΠ¼¼Æ÷°¡ ¾ø´Â °æ¿ì¸¦ »óÇdz»¾ÏÁ¾(carcinoma in situ)¶ó°í ÇÑ´Ù. ±×¸®°í ¹Ù´Ú¸·À» ¶Õ°í ¹ØÀÇ ¹öÆÀÁ¶Á÷À¸·Î Ä§¹üÇØ ³ª°¡´Â °æ¿ì¸¦ Ä§À±¾Ï(invasive cancer)¶ó°í ÇÑ´Ù.
  
  Àڱøñ¾ÏÀº ¿©·¯ ¸íÀÇ »ó´ë¿Í ¼º°ü°è¸¦ °¡Áö´Â ¿©ÀÚ, ±×¸®°í Ã¹ ¼º°æÇèÀÇ ³ªÀ̰¡ ¾î¸° ¿©ÀÚ¿¡°Ô¼­ ÈçÇÏ°í ¶Ç »çȸÀû, °æÁ¦Àû ¼öÁØÀÌ ³·Àº »ç¶÷¿¡°Ô¼­ Àß °É¸®´Â °ÍÀ¸·Î µÇ¾î ÀÖ´Ù. ÀÌ·± °ÍÀ¸·Î ¹Ì·ç¾î Àڱøñ¼¼Æ÷ÀÇ ¾Ï¼ºº¯È­¿¡´Â ¼ºº´°ú °°Àº °¨¿°ÀÌ Áß¿äÇÒ °ÍÀ¸·Î »ý°¢µÇ°í, ¶Ç ¸î°¡Áö ¹ÙÀÌ·¯½ºÀÇ °¨¿°ÀÌ Àڱøñ¾ÏÀÇ ¿øÀÎÀ̶ó´Â °ÍÀÌ ¹àÇôÁ® ÀÖ´Ù.
  
  Àڱøñ¾ÏÀÇ Áø´Ü¹æ¹ýÀ¸·Î´Â Áú¼¼Æ÷°Ë»ç, ÄÝÆ÷½ºÄÚÇÇ, »ý°Ë(biopsy) µîÀÌ ÀÖ´Ù. ¼¼Æ÷°Ë»ç¶õ Á¶±âÁø´Ü ¸ñÀûÀ¸·Î °¡Àå ¸¹ÀÌ »ç¿ëµÇ´Â ¹æ¹ýÀ¸·Î ¼ØºÀÀ¸·Î ÀڱøñÀ»¸¦ ¹®Áú·¯¼­ Àڱøñ»óÇǼ¼Æ÷¸¦ ¾ò°í À̰ÍÀ» Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© »óÇǼ¼Æ÷ÀÇ º¯È­¸¦ º¸´Â °ÍÀÌ´Ù. ÄÝÆ÷½ºÄÚÇǶõ ÀÚ±ÃÀÇ ¸ñÀ» 4~10¹è Á¤µµ È®´ëÇØ¼­ º¸´Â ÀÏÁ¾ÀÇ È®´ë°æ°Ë»çÀ¸·Î Àڱøñ¾ÏÀ¸·Î ÀÎÇÑ ÀڱøñÀÇ º´Àûº¯È­¸¦ °üÂûÇÏ¿© Áø´ÜÇϴ °ÍÀÌ´Ù. »ý°Ë¶õ Áø´ÜÀ» À§Çؼ­ Á÷Á¢ ÀڱøñÀÇ Á¶Á÷À» ¶¼¾î Ã¤ÃëÇÏ¿© Çö¹Ì°æÀ¸·Î °üÂûÇÏ¿© Áø´ÜÇϴ °ÍÀ¸·Î °¡Àå Á¤È®ÇÑ Áø´Ü¹ýÀÌ´Ù.
  
  Ä¡·á·Î´Â º´ÀÇ ÁøÇàÁ¤µµ¿¡ µû¶ó ´Ù¸£°ÚÁö¸¸ ¾ÏÀÇ ÁøÇàÀÌ °ÅÀÇ ¾ø¾î Çü¼ºÀÌ»óÀ̳ª Á¦ÀÚ¸®¾ÏÁ¾ ¶Ç´Â ¾ÆÁÖ Á¶±Ý Ä§À±ÇÏ¿´À» °æ¿ì¿¡´Â ¼ö¼úÀû¿ä¹ýÀ¸·Î ÀÚ±ÃÀ» ÀûÃâÇϴ °ÍÀÌ Ä¡·áÀÇ ¿øÄ¢ÀÌ°í ¸¹Àº ÁøÇàÀ» º¸¿© ´Ù¸¥ Á¶Á÷À¸·Î ¾ÏÀǠħÀ±ÀÌ ÀÖÀ» °æ¿ì¿¡´Â ¹æ»ç¼± Ä¡·á¸¦ ¿øÄ¢À¸·Î ÇÑ´Ù.
¿µ¹® advanced cancer ÇÑ±Û ÁøÇà¾Ï
¼³¸í   
  Á¶±â¾Ï¿¡ ´ëÇÑ ¸»·Î ¾ÏÀÇ °æ°ú°¡ ÁøÇàµÈ °ÍÀ» ¸»ÇÑ´Ù.
¿µ¹® lung cancer ÇÑ±Û Æó¾Ï
¼³¸í   
  ÇãÆÄ¿¡ »ý±â´Â ¾Ç¼ºÁ¾¾çÀÌ´Ù. °¡Àå ¿¹Èİ¡ ³ª»Û Á¾¾çÁßÀÇ Çϳª·Î½á Á¶±â¹ß°ßÀÌ ¾î·Æ°í Áõ¼¼ ¶ÇÇÑ ´Ê°Ô ³ªÅ¸³ª¼­, ±× Á¾¾çÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£³ª Ä¡·áÈÄ¿¡µµ ´ë°³ 8%¸¸ÀÌ 5³â »ýÁ¸ÀÌ °¡´ÉÇÑ ¾Ç¼ºÁ¾¾çÀÌ´Ù. À¯¹ßÀÎÀڷδ ´ëÇ¥ÀûÀ¸·Î ´ã¹è°¡ ¾Ë·ÁÁ® ÀÖÀ¸¸ç, À¯ÀüÀûÀΠ¿ä¼Òµµ ¾î´À Á¤µµ ±â¿©Çϴ °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù.
¿µ¹® cancer chemotherapy ÇÑ±Û Ç×¾ÏÈ­Çпä¹ý
¼³¸í   
  È­ÇÐÀû ¹°ÁúÀ» ÀÌ¿ëÇÏ¿© ¾ÏÀ» Ä¡·áÇϴ °ÍÀ» ¸»ÇÑ´Ù. À̶§ »ç¿ëµÇ´Â ¹°ÁúÀ» Ç×¾ÏÁ¦¶ó°í ÇÑ´Ù. ÀÌ»óÀûÀΠÇ×¾ÏÁ¦´Â Á¤»óÀûÀΠ¼¼Æ÷¿¡´Â ÀÌ»óÀÌ ¾ø°í ´ÜÁö ¾Ï¼¼Æ÷¿¡¸¸ Ä¡¸íÀûÀΠȿ°ú¸¦ ³ªÅ¸³»¾î¾ß ÇÑ´Ù. ÀÌ·¸°Ô ÇÏ·Á¸é ¾Ï¼¼Æ÷¸¸ÀǠƯÀÌÇѠƯ¼ºÀ» ÀÌÇØÇÏ°í ±×°÷¿¡¸¸ ÀÛ¿ëÇϴ ¾à¹°À» °³¹ßÇÏ¿©¾ß ÇÑ´Ù. ÃÖ±Ù ´ëºÎºÐÀÇ Ç×¾ÏÁ¦´Â ¾Ï¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ¿ùµîÈ÷ Áõ½ÄÀ» »¡¸®ÇѴٴ Ư¼ºÀ» ÀÌ¿ëÇϰí ÀÖ´Ù. Áõ½ÄÀÌ ºü¸£´Ù´Â °ÍÀº À¯ÀüÁ¤º¸¸¦ °¡Áö°í Àִ DNAÀÇ º¹Á¦°¡ ºü¸£´Ù´Â °ÍÀ» ÀǹÌÇÑ´Ù. ¸¸¾à DNAÀÇ º¹Á¦¸¦ ¹æÇØÇÑ´Ù¸é Áõ½ÄÀÌ ¾ÆÁÖ ºü¸¥ ¾Ï¼¼Æ÷¿¡°Ô´Â Ä¡¸íÀûÀÌÁö¸¸ ¿µ¿øÈ÷ Áõ½ÄÀ» ÇÏÁö ¾Ê´Â(DNAÀÇ º¹Á¦°¡ °ÅÀÇ ÇÊ¿ä¾ø´Â)½Å°æ¼¼Æ÷³ª Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿¡ ºñÇØ¼­ ¾ÆÁÖ ´À¸° Á¤»ó¼¼Æ÷¿¡¼­´Â °ÅÀÇ ¿µÇâÀ» ÁÖÁö ¸øÇÑ´Ù. ÇÏÁö¸¸ ½Åü¿¡¼­µµ Á¤»óÀûÀ¸·Î Áõ½ÄÀÌ ¾Ï¼¼Æ÷¿Í ºñ½ÁÇÑ ¼öÁØÀ¸·Î ÀϾ´Â ¼¼Æ÷°¡ Àִµ¥ ±×°ÍÀº ¸Ó¸®Ä«¶ôÀ» ¸¸µå´Â ¸ð³¶¼¼Æ÷¿Í ¼ÒÈ­°üÀÇ Á¡¸·À» ÀÌ·ç´Â ¼¼Æ÷¿Í Ç÷¾×ÀÇ ¼¼Æ÷¸¦ ¸¸µå´Â °ñ¼ö ¼¼Æ÷ÀÌ´Ù. ±×·¯¹Ç·Î Ç×¾ÏÁ¦¸¦ »ç¿ëÇÒ °æ¿ì ÀÌ·± ¼¼Æ÷°¡ ¾Ï¼¼Æ÷¿Í ¸¶Âù°¡Áö·Î Ä¡¸íÀûÀΠ¿µÇâÀ» ÀÔÀ» °ÍÀº ´ç¿¬ÇÏ´Ù(±×·¡¼­ Ç×¾ÏÁ¦ Ä¡·á½Ã¿£ ¸Ó¸®°¡ ºüÁö°í ¼ÒÈ­ºÒ·®ÀÌ À߿´Ù).
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • gallbladder cancer
    ¾µ°³¾Ï, ´ã³¶¾Ï
  • hereditary nonpolyposis colorectal cancer
    1. À¯Àü¼ººñÆú¸³À߷ϰðâÀÚ¾Ï 2. À¯Àü¼ººñÆú¸³´ëÀå¾Ï
  • infiltrating cancer
    ħÀ±¾Ï
  • integrated cancer management
    ÅëÇÕ¾ÏÄ¡·á
  • laryngeal cancer
    ÈĵξÏ
  • liver cancer
    °£¾Ï
  • medullary cancer
    ¼ÓÁú¾Ï, ¼öÁú¾Ï
  • metastatic cancer
    ÀüÀ̾Ï
  • occult cancer
    ÀáÀç¾Ï
  • occupational cancer
    Á÷¾÷¾Ï
  • papillary cancer
    À¯µÎ¸ð¾ç¾Ï
  • primary cancer
    ¿ø¹ß¾Ï
  • prostatic cancer
    Àü¸³»ù¾Ï, Àü¸³¼±¾Ï
  • recurrent cancer
    Àç¹ß¾Ï
  • renal cancer
    ÄáÆÏ¾Ï, ½ÅÀå¾Ï
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • renal cancer
    ÄáÆÏ¾Ï, ½ÅÀå¾Ï
  • thyroid papillary cancer
    °©»ó»ùÀ¯µÎ¾ÏÁ¾
  • undifferentiated cancer
    ¹ÌºÐÈ­¾Ï
  • cancer pain
    ¾ÏÅëÁõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • occupational cancer
    Á÷¾÷¾Ï
  • papillary cancer
    À¯µÎ¸ð¾ç¾Ï
  • primary cancer
    ¿ø¹ß¾Ï
  • radiation-induced cancer
    ¹æ»ç¼±À¯¹ß¾Ï
  • recurrent cancer
    Àç¹ß¾Ï
  • retrograde cancer
    ÅðÇà¾Ï
  • small cell lung cancer
    ÀÛÀº¼¼Æ÷ÇãÆÄ¾Ï, ¼Ò¼¼Æ÷Æó¾Ï
  • soft cancer
    (¢¡medullary carcinoma) ¼ÓÁú¾ÏÁ¾, ¼öÁú¾ÏÁ¾
  • solid cancer
    °íÇü¾Ï
  • integrated cancer management
    ÅëÇÕ¾ÏÄ¡·á
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 13 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • abscess of prostate
    Àü¸³¼± ³ó¾ç
  • prostate
    Àü¸³»ù, Àü¸³¼±(îñí¡àÍ).
  • prostate
    Àü¸³»ù
  • prostate
    Àü¸³¼±
  • prostate
    Àü¸³¼±(îñí¡àÍ)
  • prostate capsule
    Àü¸³¼±ÇǸ·
  • prostate carcinoma
    Àü¸³¼±¾ÏÁ¾(îñí¡àÍäßðþ)
  • prostate gland
    Àü¸³»ù, Àü¸³¼±(îñí¡àÍ).
  • prostate gland
    Àü¸³¼±
  • prostate specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • prostate utricle
    Àü¸³¼±¼Ò½Ç
  • prostate-specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
  • prostate-specipic antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • prostate
    Àü¸³»ù
  • prostate
    Àü¸³¼±
  • prostate
    Àü¸³¼±(îñí¡àÍ)
  • prostate capsule
    Àü¸³¼±ÇǸ·
  • prostate carcinoma
    Àü¸³¼±¾ÏÁ¾(îñí¡àÍäßðþ)
  • prostate gland
    Àü¸³»ù, Àü¸³¼±(îñí¡àÍ).
  • prostate gland
    Àü¸³¼±
  • prostate specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • prostate utricle
    Àü¸³¼±¼Ò½Ç
  • prostate-specific antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø(îñí¡àÍ÷åì¶ù÷ê«)
  • prostate-specipic antigen
    Àü¸³¼±Æ¯ÀÌÇ׿ø
  • septum of prostate
    Àü¸³»ù»çÀ̸·
  • transurethral incision of prostate
    Àü¸³¼±°æ¿äµµÀý°³¼ú
  • transurethral resection of prostate
    Àü¸³¼±°æ¿äµµÀýÁ¦(îñí¡àÍÌèèñÔ³ôîð¶).
  • advanced cancer
    ÁøÇà¾Ï(òäú¼ ).
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
BPH Benign Prostate(Prostatic) Hypertrophy(Hyperplasia); Àü¸³¼± ºñ´ë(Áõ)
PSA Prostate(Prostatic)-Specific Antigen; Àü¸³¼± ƯÀÌ Ç׿ø
TURP Trans-Urethral Resection of the Prostate; ¿äµµ½Ä (Àü¸³¼±) ÀýÁ¦¼ú
ACPP adrenocortical polypeptide; prostate-specific acid phosphatase
APS adenosine phosphosulfate; American Pain Society; American Pediatric Society; American Physiological ...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
HPC hereditary prostate cancer
PC-3 prostate cancer cell line
BPH Benign Prostate Hyperplasia
CSAP Cryosurgical ablation of the prostate
DP Dorsal prostate
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • lip cancer
    ÀÔ¼ú ¾Ï
  • mammary cancer
    À¯¾Ï
    Á¥»ù¿¡¼­ ¹ß»ýÇÏ´Â À¯¹æÀÇ ¾Ï. Àڱ⠰˻ç¹ýÀ¸·Î Á¶±â ¹ß°ßÀÌ °¡´ÉÇÏ´Ù. ³²¼ºÀÇ À¯¹æ ¾ÏÀº ¿©¼ºÀÇ ¾à 1/100·Î ¸Å¿ì µå¹°´Ù. ¹éÀÎ, ƯÈ÷ ºÏÀ¯·´°èÀÇ ¿©¼º¿¡°Ô ¸¹Àºµ¥, ÇÏ¿ÍÀÌ °ÅÁÖÀÚÀÇ Á¶»ç
  • mouth cancer
    ±¸°­ ¾Ï
  • occupational cancer
    Á÷¾÷ ¾Ï
  • oral cancer
    ±¸°­ ¾Ï
    Àüü ¾Ï ¹ß»ý ºóµµ¿¡¼­ ¾à 3¡­4%¸¦ Â÷ÁöÇÏ´Â ±¸°­ ¾ÏÀº Çô, »´, Ä¡ÁÖÁ¶Á÷, ¶Ç´Â ±¸ÀεÎÀÇ ¾î´À ºÎÀ§¿¡µµ ħ¹üÇÒ ¼ö ÀÖ´Ù. ÀÌ´Â ±¸°­ ³»ÀÇ ¹ß»ý À§Ä¡¿¡ µû¶ó ´Þ¶óÁö±â´Â ÇÏÁö¸¸ ´ë°³ ¿©ÀÚº¸´Ù´Â ³²ÀÚ¿¡°Ô¼­ ¾à 2~6¹è ¸¹ÀÌ ¹ß»ýÇÏ¸ç ¿ì¸® ³ª¶ó¿¡¼­´Â 1³â¿¡ ¾à õ ¸í ³»Áö ÀÌ Ãµ¸íÀÇ »õ·Î¿î ±¸°­ ¾Ï ȯÀÚ°¡ ¹ß»ýÇϱ⠶§¹®¿¡ ±¸°­ ¾ÏÀ¸·Î Åõº´ ÁßÀΠȯÀÚ¸¸µµ ¼ö ¸¸ ¸í¿¡ À̸¥´Ù. 1996³â¿¡ ½ÃÇàÇÑ ÈÄÇ⼺ ¿¬±¸¿¡ ÀÇÇϸé Àüü ±¸°­ ¾Ï ȯÀÚÀÇ Æò±Õ 5³â »ýÁ¸À²Àº ¾à 46%·Î ¹Ý ÀÌ»óÀÇ È¯ÀÚ°¡ 5³â À̳»¿¡ »ç¸ÁÇÏ´Â °ÍÀ¸·Î Á¶»çµÈ¹Ù ÀÖ´Ù. ±¸°­ ¾ÏÀÇ À¯º´·üÀº ¿¬·É Áõ°¡¿Í °ü·ÃÀÌ ÀÖ´Ù. 40¼¼ ÀÌÈÄ¿¡ ¹ß»ý·üÀÌ ±ØÀûÀ¸·Î Áõ°¡Çϱ⠽ÃÀÛÇÏ¿© 60¼¼ÀÇ ¿¬·É¿¡¼­ ÀÏÁ¤ÇÑ À¯Áö °î¼±À» Çü¼ºÇÑ´Ù. ¾î¶² ¿ä¼Ò°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Å« ¿µÇâÀ» ³¢Ä¡´Â°¡¿¡ ´ëÇÑ ¹®Çå ¿¬±¸¿¡¼­ ´ã¹è¿Í ¼úÀÌ ¸ðµç ±¸°­ ¾ÏÀÇ 75%¸¦ ¾ß±âÇØ ÀÌ Áúȯ¿¡ °¡Àå Å« ¿µÇâÀ» ¹ÌÄ¡´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. Èí¿¬°ú °úÀ½ÀÌ °¢°¢ ±¸°­ ¾ÏÀÇ À§Ç輺À» Áõ°¡½ÃŰ´Â ¹Ý¸é, ±×µéÀÇ »óÇÕÈ¿°ú´Â ±× ¸î ¹èÀÎ °ÍÀ¸·Î ³ªÅ¸³ª¼­ °ñÃÊ¿¡ ¾ËÄÝ Áßµ¶À̶ó¸é Á¤»óÀÎÀÇ ¾à 30¹è ÀÌ»ó ÀÌȯÀ²ÀÌ ³ô¾ÆÁø´Ù. ±¸°­ ¾ÏÀÇ ÈçÇÑ Àü±¸ Áõ»óÀ¸·Î ¾Ë·ÁÁø ¹é¹ÝÁõÀº ±¸°­ Á¡¸·¿¡ Èò ¹éŸ¦ º¸ÀÌ´Â º´º¯À¸·Î ÀÌ ÁúȯÀÌ ¾ÏÁ¾À¸·Î ÁøÇàµÉ È®·üÀº 0.1%~36%ÀÇ ¸Å¿ì ´Ù¾çÇÑ ÆíÂ÷·Î º¸°íµÇ°í ÀÖÀ¸³ª ÀϹÝÀûÀ¸·Î´Â 10Áõ·Ê Áß 1Áõ·Ê°¡ ÀÌÇàµÇ´Â °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Àß ÀûÇÕµÇÁö ¾Ê´Â Ʋ´Ï³ª ¿À·¡ »ç¿ëÇÏ¿© ¸¶¸ðµÇ°í ³¯Ä«·Î¿öÁø ±Ý°ü µî¿¡ ÀÇÇÏ¿© Çù Á¡¸·À̳ª Çô, ¹«Ä¡¾Ç Ä¡Á¶Á¤ Á¡¸· µî¿¡ ¹ß»ýµÇ´Â ±Ë¾ç¼º º´º¯Àº Á¾±¹¿¡´Â ±¸°­ ¾ÏÀ¸·Î ÀüÀ̵DZ⠽¬¿î °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ¾î ÁÖ±âÀûÀÎ Ä¡°ú °ËÁøÀÌ ÇÊ¿äÇÏ´Ù. ±¸°­ ¾ÏÀÇ À§Çè ¿ä¼Ò Áß¿¡´Â À¯ÀüÀû ¿ä¼Òµµ ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ´Ù. ƯÁ¤ Áý´Ü Áß¿¡´Â ¾ÏÀ» °¡Áö°í ÀÖ´Â °¡Á·ÀÌ ÀÖÀ¸¸é ±¸°­ ¾ÏÀÇ ¹ß»ý À§Ç輺ÀÌ ³ôÀº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. Èí¿¬°ú À½ÁÖ°¡ ±¸°­ ¾Ï ¹ß»ý¿¡ °¡Àå Áß¿äÇÑ ¿äÀÎÀ̱⠶§¹®¿¡ Áß´ÜÇϰųª ÃÖ¼ÒÇÑ ÁÙÀÌ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇÏ´Ù. °Ç°­ÇÑ ½Ä»ýȰÀº ±¸°­ ¾ÏÀ» ¿¹¹æÇÒ ¼ö ÀÖ´Ù. ½Å¼±ÇÑ °úÀÏÀ̳ª ³ì»ö ä¼Ò´Â ±¸°­ ¾Ï ¹ß»ý·üÀ» °¨¼Ò½Ãų ¼ö ÀÖ°í, ÀÌ´Â ºñŸ¹Î A, C, E°¡ ÇÔÀ¯µÈ À½½ÄÀÌ ¿¹¹æ È¿°ú¸¦ °®´Â´Ù´Â »ç½ÇÀ» µÞ¹ÞħÇÑ´Ù. ±¸°­ Á¡¸·À» µ¥ÀÏ Á¤µµÀÇ ¶ß°Å¿î À½½ÄÀ̳ª ÀڱؼºÀÇ À½½ÄÀº ÇÇÇϵµ·Ï ÇÏ´Â °ÍÀÌ ÁÁ´Ù. HPVÀÇ ¹ßÇöÀ̳ª P53 À¯Àü ÀÎÀÚÀÇ º¯À§¿Í °°Àº ƯÁ¤ À¯ÀüÇÐÀû ¶Ç´Â Ãʱ⠼¼Æ÷ º¯È­°¡ ±¸°­ ¾Ï°ú °ü·ÃÀÌ ÀÖ´Ù´Â ¹ß°ßÀº ÃÖ±Ù ÁÖ¸ñ¹Þ°í ÀÖ´Â ¿¬±¸ÀÌ´Ù. °¡±î¿î ¹Ì·¡¿¡´Â ±¸°­ ¾ÏÀÇ À§Ç輺ÀÌ ³ôÀº ȯÀÚÀÇ ±¸°­ Á¡¸·À» ÁÖ±âÀûÀ¸·Î °Ë»çÇϰųª Ãʱ⠼¼Æ÷ º¯È­¸¦ º¸À̴ ȯÀÚ¸¦ ÀÎÁöÇÏ´Â °ÍÀÌ °¡´ÉÇÒ °ÍÀÌ´Ù. ±¸°­ ¾ÏÀÇ Á¶±â ¹ß°ß°ú Ä¡·á¸¦ À§ÇÑ À¯¿ëÇÑ ±â¼úÀÇ °³¹ßÀº ÀÌ ºÐ¾ß¿¡¼­ ±â´ëµÈ´Ù. ±¸°­ ¾ÏÀº ¹ß»ý Ãʱ⿡´Â º°´Ù¸¥ Áõ»óÀ» º¸ÀÌÁö ¾Ê°í ¼­¼­È÷ ÁøÇàµÇ±â ¶§¹®¿¡ Á¶±â ¹ß°ßÀÌ ¹«Ã´ ¾î·Æ´Ù. ±¸°­ ¾Ç¾È¸é ¿µ¿ªÀÇ ¾ÏÀÇ Á¶±â ¹ß°ßÀº ¿©·¯ °¡Áö ÀÓ»óÀûÀÎ ¹ß°ßÀÌ ±âÃʰ¡ µÇ´Âµ¥ Ãʱ⿡´Â ´ë°³ ºÓÀº È«¹ÝÁõÀ» º¸À̸ç Á¡¸·ÀÌ °ÅÄ¥¾îÁö°í ¾à°£ À¶±âµÇ³ª À̶§´Â ¿°Áõ¼º º´¼Ò¿Í ºñ½ÁÇÏ¿© °¨º°ÀÌ °ï¶õÇÏ´Ù. ÀÌÈÄ ÁøÇàµÇ¾î ÀԾȿ¡ Èò ¸·ÀÌ »ý±â°Å³ª ÀÔ¾ÈÀÌ Çæ¾î ±Ë¾çÀÌ »ý±â°í º¸¸§ ÀÌ»ó ³´Áö ¾Ê°í Áö¼ÓµÇ´Â °æ¿ìµµ ÀÖ´Ù. ÀԾȿ¡ ¸¸¼ºÀûÀ¸·Î ¹é»ö º´¼Ò°¡ ÀÖ´Â °æ¿ì, ¸ñ¿¡ ¸Û¿ïÀÌ »ý±â°í ¾ø¾îÁöÁö ¾Ê´Â °æ¿ì ±¸°­ ¾ÏÀÌ ÀǽɵǹǷΠÁ» ´õ ¼¼¹ÐÇÑ Áø´ÜÀ» ¹Þ¾Æº¸´Â °ÍÀÌ ±ÇÀåµÇ¸ç Á¶±â Áø´Ü ½Ã »ýÁ¸À²Àº ÇöÀúÇÏ°Ô ³ô¾ÆÁö°Ô µÈ´Ù. ±¸°­ ¾Ï Ä¡·á ¹æ¹ýÀº ´ëÇ¥ÀûÀ¸·Î ¿Ü°úÀû ¼ö¼ú, ¹æ»ç¼± ¿ä¹ý, Ç×¾Ï ¿ä¹ýÀ¸·Î ÀÌ·ç¾îÁö¸ç ´Üµ¶À¸·Î ¶Ç´Â º¹ÇÕÀûÀ¸·Î ½ÃÇàµÈ´Ù. ÃÖ±Ù¿¡ ¸é¿ª ¿ä¹ý, ±¤ ¿¡³ÊÁö ¿ä¹ý µîÀÌ °³¹ßµÇ°í ÀÖÀ¸³ª ¾ÆÁ÷ ÀÓ»óÀûÀ¸·Î Ȱ¹ßÈ÷ ÀÌ¿ëµÇ°í ÀÖÁö´Â ¸øÇÏ´Ù. ±¸°­ ¾Ç¾È¸é ºÎÀ§ÀÇ Á¾¾çÀÇ ÀýÁ¦ ½Ã¿¡´Â Åë»ó ¾Ç¾È¸é ºÎÀ§ÀÇ °á¼ÕÀ¸·Î ±â´É Àå¾Ö¿Í ¾È¸ð ÃßÇü µîÀÇ ½É¹ÌÀûÀÎ ¼Õ»ó°ú ÀÌ¿¡ µû¸¥ Á¤½Å ½É¸®Àû ¹®Á¦Á¡À» ¾ß±âÇÒ ¼ö ÀÖ´Ù. ±¸°­ ¾Ï ÀýÁ¦¼ú ÈÄ ¾Ç°ñ ¹× ¿¬Á¶Á÷ °á¼ÕÀÌ ÀÖ´Â °æ¿ì¿¡ ¾Ç°ñ Àç°ÇÀ» ´Ü¼øÈ÷ º¹¿øÀ̶ó´Â °³³äÀ» ¶°³ª ½É¹ÌÀûÀ̰í ÀúÀÛ ±â´ÉÀÇ È¸º¹À̶ó´Â Â÷¿ø¿¡¼­ Àç°ÇÇÏ¿© »çȸÀûÀ¸·Î º¹±ÍÇÒ ¼ö ÀÖµµ·Ï ÇÏ´Â °ÍÀÌ Áß¿äÇÏ´Ù.
  • pancreas cancer
    ÃéÀå ¾Ï
    ÃéÀå¿¡ »ý±â´Â ¾Ï. ÃéÀå
  • pancreatic cancer
    ÃéÀå ¾Ï
  • radiation induced cancer
    ¹æ»ç¼± À¯¹ß ¾Ï, X¼± ¾Ï
  • renal cancer
    ½Å ¾Ï
  • retrograde cancer
    ÅðÇ༺ ¾Ï
  • scar cancer
    ¹ÝÈç ¾Ï
    ¹ÝÈçÀÌ ¾ÏÀÇ ¿øÀÎ, Æó ¾Ï¿¡ ¸¹´Ù.
  • smoker s cancer
    Èí¿¬ÀÚ ¾Ï
  • tongue cancer
    ¼³ ¾Ï
    Çô¿¡ »ý±â´Â ¾Ï.
  • vaginal cancer
    Áú ¾Ï
  • water cancer
    ¼ö¾Ï. ±«»ç¼º ±¸³»¿°
    µ¿ÀǾî=gangrenous stomatitis.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
nodular hyperplasia of prostate Glandular and stromal hyperplasia occurring very commonly in the middle and lateral lobes of older men, forming nodules that may increasingly obstruct the urethra.
Synonym: benign prostatic hypertrophy.
(05 Mar 2000)
inferolateral surface of prostate The surface of the prostate facing the body of the pubis and the pelvic diaphragm.
Synonym: facies inferolateralis prostatae.
(05 Mar 2000)
isthmus of prostate The narrow middle part of the prostate anterior to the urethra.
Synonym: isthmus prostatae.
(05 Mar 2000)
elevator muscle of prostate <anatomy> In the male, the most medial fibres of the levator ani (pubococcygeus) muscle that extend from the pubis into the fascia of the prostate.
Synonym: musculus levator prostatae, elevator muscle of prostate.
(05 Mar 2000)
fascia of prostate The condensation of pelvic visceral fascia that encloses the prostate gland.
Synonym: fascia prostatae.
(05 Mar 2000)
female prostate Term sometimes applied to the periurethral glands in the upper part of the urethra in the female.
(05 Mar 2000)
lobe of prostate One of the lateral lobes (right or left) or the middle lobe or isthmus of the prostate; in the adult the lobes are ill-defined.
Synonym: lobus prostatae.
(05 Mar 2000)
American Cancer Society <address, organisation>
American Cancer Society, National Headquarters, 1599 Clifton Road, NE, Atlanta, GA 30329 USA.
Tel: 00 1 404 320-3333
(05 Feb 1998)
bladder cancer The most common warning sign of bladder cancer is blood in the urine. The diagnosis of bladder cancer is supported by findings in the medical history and examination, blood, urine, and X-ray tests, and confirmed with a biopsy (usually during a cystoscope exam). Treatment of bladder cancer depends on the growth, size, and location of the tumour.
(12 Dec 1998)
bladder cancer risks Smoking is a major risk factor. Cigarette smokers develop bladder cancer 2-3 times more often than do nonsmokers. Quitting smoking reduces the risk of bladder cancer, lung cancer, several other types of cancer, and a number of other diseases as well. Workers in some occupations are at higher risk of developing bladder cancer because of exposure to carcinogens (cancer-causing substances) in the workplace. These workers include people in the rubber, chemical, and leather industries, as well as hairstylists, machinists, metal workers, printers, painters, textile workers, and truck drivers.
(12 Dec 1998)
bone cancer <oncology> A general term to imply malignant tumour growth in bone.
(27 Sep 1997)
bovine cancer eye A malignant squamous cell carcinoma of cattle, especially the Hereford breed, that originates in the conjunctival mucous membranes or the surrounding skin; it occurs principally in range cattle having unpigmented skin around the eye and living in regions of intense sunlight.
(05 Mar 2000)
BRCA1 breast cancer susceptibility gene This mutated (changed) version of the BRCA1 gene makes a person susceptible to developing breast cancer.
(12 Dec 1998)
breast cancer <oncology> The uncontrolled growth of malignant breast tissue.
Breast cancer is currently the most common cancer in women and the leading cause of cancer-related death in the 15-54 age group.
Strong risk factors include a prior history for breast cancer or a positive family history for breast cancer.
Early detection is possible through the use of monthly breast self-examination, annual clinical exams and mammography.
WWW: cancerNET document for patients
WWW: cancerNET document for clinicians
(05 Jan 1998)
breast cancer susceptibility genes Inherited factors that predispose to breast cancer. Put otherwise, these genes make one more susceptible to the disease and so increase the risk of developing breast cancer. Two of these genes, BRCA1 and BRCA2, have been identified (and prominently publicised). Several other genes (those for the Li-Fraumeni syndrome, Cowden disease, Muir-Torre syndrome, and ataxia-telangiectasia) are also known to predispose to breast cancer. However, since all of these known breast cancer susceptibility genes together do not account for more than a minor fraction (1/5th at most) of breast cancer that clusters in families, it is clear that more breast cancer genes remain to be discovered.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á